Is this the beginning of “the” turnaround?

On first glance this was significantly better than I think most expected.

From the ASX announcement.

H2 EBITDA OF 2.2m a 15.4m improvement from H1.

H2 gross margins up to 81% from 71%.

Cost to operate the business dropped 11.9m in H2 from H1.

Operating cash flow + 40% YoY to 3.7m.

SaaS revenue +21.8% YoY (CC) contributing to a total revenue of 84.4m.

Record H2 sales: FY23 ACV +20.2% to 76.8m (CC).

ACV churn a record low rates of 3.8%

Performance and Health vertical ACV grew 28% YoY (CC).